A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

2011716 citationsJournal Article

Authors

Christos Hatzis · Nuvera Biosciences (United States)

Abstract

A genomic predictor combining ER status, predicted chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.

Topics & Keywords

Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 305, Issue 18, pp. 1873-1873

DOI: 10.1001/jama.2011.593

Field-Weighted Citation Impact: 19.04